Share

Advocacy in Action: Election Results, EDCs, Diabetes Awareness, and More

What’s Happening in Washington Election Results – While Republicans held onto the majority in the US Senate, Democrats picked up more than the 23 seats needed to gain control of the House of Representatives when the 116th Congress convenes in January.  The Democrats’ win of the House will portend serious changes in Washington, as the...
Share

Analysis Estimates the Positive Impact of Empagliflozin on Life Expectancy in Adults with Type 2 Diabetes and Established Cardiovascular Disease

Treatment with empagliflozin may positively impact life expectancy in adults with type 2 diabetes and established cardiovascular disease, according to results from the EMPA-REG OUTCOME trial recently published in Circulation. Using actuarial methods and assuming that the demonstrated beneficial effects of empagliflozin remain consistent with long-term use, empagliflozin was estimated to extend life expectancy by one...
Share

Call for Nominations: Endocrine Society’s Award for Excellence in Science and Medical Journalism

The Endocrine Society is calling for nominations for the 12th annual Award for Excellence in Science and Medical Journalism. The award recognizes outstanding reporting that enhances public understanding of health issues pertaining to the field of endocrinology. Endocrinologists are physicians and scientists who untangle complex symptoms to diagnose, treat, research, or cure hormone-related conditions. These...
Share

Aflibercept Injection Improved Diabetic Retinopathy and Reduced Vision-Threatening Complications in Phase 3 Trial

The Phase 3 PANORAMA trial evaluating aflibercept injection in patients with moderately severe and severe non-proliferative diabetic retinopathy (NPDR) met its one-year (52-week) primary endpoint and key secondary endpoints, the drug’s manufacturer announced today. Regeneron Pharmaceuticals is marketing the drug as EYELA. On the primary endpoint at one year, 80% and 65% of patients receiving...